Prescribing trends for sodium valproate in Ireland
Prescribing trends for sodium valproate in Ireland
复制标题
DOI：
10.1016/j.seizure.2016.01.019
复制
发表时间：
2016-03-01
影响因子：
3
通讯作者：
Doherty, Colin P.
中科院分区：
文献类型：
--
作者：
Murphy, Sinead;Bennett, Kathleen;Doherty, Colin P.
目的：本研究旨在描述抗惊厥药物（AED）丙戊酸钠（VPA）在爱尔兰育龄妇女人群中的处方实践，新数据显示，妊娠期间服用VPA的妇女的后代发育异常率较高。对2008年至2013年期间爱尔兰社区药房开具的所有处方进行了检查，对象为来自爱尔兰所有三个药物报销计划的16-44岁女性。确定了使用抗癫痫药物的处方数和妇女数，以及该药物的农村/城市分布，沿着叶酸和口服避孕药的共同处方。所有数据分析均采用SAS v9.3进行。结果：爱尔兰的VPA处方率从2008年的3.5/1000/合格人群略微下降至2013年的3.14/1000。虽然癫痫的处方率下降，但VPA其他适应症的处方似乎有所增加。2013年，在所有社区计划中，叶酸或口服避孕药的联合处方相对较低。最后，一个地址远离学术专家中心预测更高的暴露VPA.Conclusion：最近欧洲医药局建议，VPA的替代品，在处方给育龄妇女。尽管如此，爱尔兰的VPA处方率似乎在增加，用于癫痫以外的适应症。可能有必要改善有关VPA在该人群中潜在负面影响的信息传播。(C)2016年英国癫痫协会。由爱思唯尔有限公司出版。保留所有权利。
Purpose: This study was undertaken to describe prescribing practice for the anti-convulsant drug (AED) Sodium Valproate (VPA) in an Irish population of woman of childbearing age during the period of the emergence of new data showing a high rate of developmental abnormalities in offspring of women who took VPA during pregnancy.Methods: All prescriptions dispensed from community pharmacies in Ireland between 2008 and 2013 inclusive were examined for women aged 16-44 years from all three drug reimbursement schemes in Ireland. Numbers of prescriptions and women on AEDs were identified, as was the rural/urban distribution of the drug along with co-prescribing of folic acid and the oral contraceptive pill. All data analysis was conducted using SAS v9.3.Results: The rate of prescribing of VPA in Ireland declined slightly from 3.5/1000 per eligible population in 2008 to 3.14/1000 in 2013. While rates of prescribing fell for epilepsy, there appeared to be a rise in prescription for other indications of VPA. In 2013, co-prescription of folic acid or oral contraceptives was relatively low across all community schemes. Finally, an address distant from academic specialist centers predicted a higher exposure to VPA.Conclusion: Recently the European Medicine's Agency suggested that alternatives to VPA be considered before prescribing to women of childbearing age. Despite this, the rate of VPA prescribing in Ireland appears to be increasing for indications other than epilepsy. It may be necessary to improve the dissemination of information about the potential negative effects of VPA in this population. (C) 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.